Clinical Trials Logo

Alpha 1-Antitrypsin Deficiency clinical trials

View clinical trials related to Alpha 1-Antitrypsin Deficiency.

Filter by:

NCT ID: NCT01379469 Terminated - Liver Cirrhosis Clinical Trials

Carbamazepine in Severe Liver Disease Due to Alpha-1 Antitrypsin Deficiency

CBZ
Start date: January 2012
Phase: Phase 2
Study type: Interventional

The primary objective is to determine if the medication Carbamazepine, can be used as a therapy for patients with severe liver disease due to Alpha-1-Antitrypsin Deficiency .

NCT ID: NCT01357460 Terminated - Clinical trials for Hereditary Emphysema (Alpha 1-antitrypsin Deficiency)

Endoscopic Lung Volume Reduction in Patients With Advanced Emphysema Due to alpha1 Antitrypsin Deficiency

Start date: May 2011
Phase: N/A
Study type: Interventional

Patients with advanced heterogeneous emphysema due to alpha1 antitrypsin deficiency might benefit from endoscopic implantation of intrabronchial valves.

NCT ID: NCT01241942 Terminated - Cystic Fibrosis Clinical Trials

Phase 2 Study of Ex-vivo Perfusion and Ventilation of Lungs to Assess Transplant Suitability

Start date: December 2010
Phase: N/A
Study type: Interventional

The purpose of this research study is to perfect the technique of EVLP and learn about the safety of transplanting lungs that have been ventilated (attached to a breathing machine or ventilator to deliver oxygen) and perfused with a lung perfusion solution (Steen solution™, made by Vitrolife). This ventilation and perfusion will be done outside the body (ex-vivo) in a modified cardiopulmonary bypass circuit (the kind of device used routinely during most heart surgeries). The purpose of performing ex-vivo lung perfusion and ventilation (EVLP) is to learn how well the lungs work, and whether they are likely safe to transplant.

NCT ID: NCT00313144 Terminated - Clinical trials for Alpha1-antitrypsin Deficiency

Aralast alpha1-proteinase Inhibitor Surveillance Study

Start date: June 9, 2006
Phase: Phase 4
Study type: Interventional

The primary objectives of this Phase 4, open label, prospective U.S. surveillance study are to evaluate the health outcomes of Alpha 1-Antitrypsin (AAT)-deficient subjects who are initiating treatment with ARALAST on patient-related outcomes (PRO), i.e., health-related quality of life (HRQoL), healthcare resource utilization (HCRU), and various laboratory analyses to evaluate the safety of long-term administration of ARALAST. Up to 120 subjects will be enrolled and assessed for HRQoL and HCRU at baseline and every 6-months thereafter, for 2 years. A subset of subjects will be enrolled into the blood draw portion of the study, which will also include assessments of antibodies to ARALAST, and chemistry panel. Subjects will be treated according to the prescribing (attending) physician's instructions based on the prescribing information given in the ARALAST package insert.

NCT ID: NCT00005098 Terminated - Clinical trials for Alpha 1-Antitrypsin Deficiency

Study of Genotype and Phenotype in Patients With Alpha 1-Antitrypsin Deficiency

Start date: March 1999
Phase: N/A
Study type: Observational

OBJECTIVES: I. Establish cell lines from patients with alpha 1-antitrypsin deficiency in order to examine genetic traits that predispose to liver injury.